补肾强督治尫汤治疗强直性脊柱炎临床观察
|
摘要
目的
本临床对照研究目的旨在通过应用独活寄生汤为对照,观察补肾强督治尫汤治疗强直性脊柱炎的临床有效性和安全性。
方法
研究对象为符合强直性脊柱炎的西医诊断标准和中医辨证标准的患者,随机分配到补肾强督治尫汤或独活寄生汤组。观察、记录并比较其治疗前后的中医症状(包括腰骶脊背疼痛、脊背疼痛、关节肿胀、发热、腰脊活动受限、晨僵、关节发热、乏力、腰膝酸软、刺痛、口干不欲饮、小便黄、肢体困重、肌肤干燥、遗精、畏寒喜暖在内的17个中医症状)、Bath强直性脊柱炎病情活动指数、Bath强直性脊柱炎功能指数、总体背痛评分、夜间背痛评分以及患者对病情的总体评价VAS评分。
统计方法：分类资料用χ2检验,等级资料用两样本比较Wilcoxon秩和检验(校正),两样本均数比较用t检验或Wilcoxon秩和检验,自身前后比较用配对t检验或Wilcoxon配对秩和检验。统计计算采用SPSS 17.0统计软件完成统计分析。
结果
一般调查资料显示,患者平均年龄为34.1±3.8岁,平均病程4.8±2.5月。两组中医证候疗效比较显示,试验组临床痊愈率为40％,显效率为27.5%,有效率为25%,总有效率为92.5%；对照组临床痊愈率为7.5%,显效率为17.5%,有效率为35%,总有效率为60%。两组中医症状的总改善率均在50%以上。对两组次要疗效指标——Bath病情活动指数、Bath脊柱功能指数、总体背痛、夜间背痛和的患者对病情总体评价治疗前后比较显示,两组均能有效的降低各观察指标的积分。试验组7.5%患者出现消化道不适,2.5%的患者白细胞减少,无肝酶异常变化；对照组有12.5%的患者出现消化道不适,15%的患者出现白细胞减少,5%的患者发现肝酶异常。试验组的不良反应发生率远低于对照组,且停药后症状就会消失。
结论
在中医症候总疗效的比较上,补肾强督治尫汤组优于独活寄生汤组(P<0.05)。试验组在腰骶脊背疼痛、关节胀痛、腰脊活动受限、晨僵、关节作冷、刺痛、口干不欲饮、肢体困重的改善上要优于对照组(P<0.05)。对两组次要疗效指标——Bath病情活动指数、Bath脊柱功能指数、总体背痛、夜间背痛和的患者对病情总体评价治疗前后比较显示,两组均能有效的降低积分,但补肾强督治尫汤组要优于独活寄生汤组。安全性分析显示,治疗前后血、尿、大便常规、肝肾功能、心电图等未见异常改变,表明该药临床应用安全。
Objective
To observe the clinical efficacy and the safety of BuShenQiangDuZhiWangTang(BST) for treating ankylosing spondylitis(AS) by which adopted the Angelicae Pubescentis and Loranthi Decoction(APD) as controlled trial.
Methods
The patients that were consistent with AS standard of diagnostic criteria in western medicine and Chinese medicine were divided into BST group and APD group in random. Chinese symptom(including waist-sacro-back ache、backache、arthrocele、fever、lumbar vertebrae limitation of activity、early morning stiffness、joint fever、hypodynamia、waista and knee ache、pricking pain、Dry mouth、yellow urine、limbs weary、muscle and skin dry、emissions and chilly 17 Chinese symptom)、BS activity index number、BS function index、overall backache score、backache at night score and overall evaluation (VAS) score were observed and recorded both at after and before treatment time.
Statistical methods:The classification data was observed using 2 test and the ranked data by Wilcoxon rank-sum test. T-test or Wilcoxon rank-sum test was applied for group comparison. Matched t-test or Wilcoxon matched-rank-sum test was applied for self-AP:PA comparison. The statistical analysis was used with the software of SPSS17.0.
Results
General investigation data showed that the average of patients'age was 34.1±3.8years old and the course of disease was 4.8±2.5 months. Compared with the curative effect on symptom of Chinese medicine within two groups, it was showed that the clinical recovery rate of the treatment group was 40%, and the excellence rate was 27.5%, the effective rate was 25%, the total effective rate was 92.5%. While in the control group, the clinical recovery rate of the treatment group was 7.5%, and the excellence rate was 17.5%, the effective rate was 35%, the total effective rate was 60%. The total improvement rate of the symptom in Chinese medicine in both two groups were all above at 50%. To the secondary of curative effect index which including BS activity index number、BS function index、overall backache score、backache at night score and overall evaluation (VAS) score, both two groups had significant difference between before and after treatment, which all could decrease the score of the index. In the BST group, there was 7.5 percent of patients had alimentary canal complaint and 2.5 percent of patients had aleucocytosis. There was no abnormal change of liver enzyme. While in the control group, there was 12.5 percent of patients had alimentary canal complaint and 15 percent of patients had aleucocytosis. There was 5% of patients had abnormal change of liver enzyme. The adverse reaction rate of BST group was far lower than which of control group. And the adverse reaction would disappear after stopping medicine.
Conelusion
There was significant difference between two groups (P<0.05). The BST group was better than the APD group on the total curative effect of the symptom in Chinese medicine for improving the waist-sacro-back ache、backache、arthrocele、lumbar vertebrae limitation of activity、early morning stiffness、joint cold、pricking pai、Dry mouth and limbs weary (P<0.05). To the secondary of curative effect index which including BS activity index number、BS function index、overall backache score、backache at night score and overall evaluation (VAS) score, both two groups had significant difference between before and after treatment, which all could decrease the score of the index. But the BST group was better than the APD group. The analysis of safety had presented that it had not abnormal change in blood routine test、urine and stool routine test、liver and renal function test and electrocardiogram test. The BST showed that it was safe in the clinical application.
本临床对照研究目的旨在通过应用独活寄生汤为对照,观察补肾强督治尫汤治疗强直性脊柱炎的临床有效性和安全性。
方法
研究对象为符合强直性脊柱炎的西医诊断标准和中医辨证标准的患者,随机分配到补肾强督治尫汤或独活寄生汤组。观察、记录并比较其治疗前后的中医症状(包括腰骶脊背疼痛、脊背疼痛、关节肿胀、发热、腰脊活动受限、晨僵、关节发热、乏力、腰膝酸软、刺痛、口干不欲饮、小便黄、肢体困重、肌肤干燥、遗精、畏寒喜暖在内的17个中医症状)、Bath强直性脊柱炎病情活动指数、Bath强直性脊柱炎功能指数、总体背痛评分、夜间背痛评分以及患者对病情的总体评价VAS评分。
统计方法：分类资料用χ2检验,等级资料用两样本比较Wilcoxon秩和检验(校正),两样本均数比较用t检验或Wilcoxon秩和检验,自身前后比较用配对t检验或Wilcoxon配对秩和检验。统计计算采用SPSS 17.0统计软件完成统计分析。
结果
一般调查资料显示,患者平均年龄为34.1±3.8岁,平均病程4.8±2.5月。两组中医证候疗效比较显示,试验组临床痊愈率为40％,显效率为27.5%,有效率为25%,总有效率为92.5%；对照组临床痊愈率为7.5%,显效率为17.5%,有效率为35%,总有效率为60%。两组中医症状的总改善率均在50%以上。对两组次要疗效指标——Bath病情活动指数、Bath脊柱功能指数、总体背痛、夜间背痛和的患者对病情总体评价治疗前后比较显示,两组均能有效的降低各观察指标的积分。试验组7.5%患者出现消化道不适,2.5%的患者白细胞减少,无肝酶异常变化；对照组有12.5%的患者出现消化道不适,15%的患者出现白细胞减少,5%的患者发现肝酶异常。试验组的不良反应发生率远低于对照组,且停药后症状就会消失。
结论
在中医症候总疗效的比较上,补肾强督治尫汤组优于独活寄生汤组(P<0.05)。试验组在腰骶脊背疼痛、关节胀痛、腰脊活动受限、晨僵、关节作冷、刺痛、口干不欲饮、肢体困重的改善上要优于对照组(P<0.05)。对两组次要疗效指标——Bath病情活动指数、Bath脊柱功能指数、总体背痛、夜间背痛和的患者对病情总体评价治疗前后比较显示,两组均能有效的降低积分,但补肾强督治尫汤组要优于独活寄生汤组。安全性分析显示,治疗前后血、尿、大便常规、肝肾功能、心电图等未见异常改变,表明该药临床应用安全。
Objective
To observe the clinical efficacy and the safety of BuShenQiangDuZhiWangTang(BST) for treating ankylosing spondylitis(AS) by which adopted the Angelicae Pubescentis and Loranthi Decoction(APD) as controlled trial.
Methods
The patients that were consistent with AS standard of diagnostic criteria in western medicine and Chinese medicine were divided into BST group and APD group in random. Chinese symptom(including waist-sacro-back ache、backache、arthrocele、fever、lumbar vertebrae limitation of activity、early morning stiffness、joint fever、hypodynamia、waista and knee ache、pricking pain、Dry mouth、yellow urine、limbs weary、muscle and skin dry、emissions and chilly 17 Chinese symptom)、BS activity index number、BS function index、overall backache score、backache at night score and overall evaluation (VAS) score were observed and recorded both at after and before treatment time.
Statistical methods:The classification data was observed using 2 test and the ranked data by Wilcoxon rank-sum test. T-test or Wilcoxon rank-sum test was applied for group comparison. Matched t-test or Wilcoxon matched-rank-sum test was applied for self-AP:PA comparison. The statistical analysis was used with the software of SPSS17.0.
Results
General investigation data showed that the average of patients'age was 34.1±3.8years old and the course of disease was 4.8±2.5 months. Compared with the curative effect on symptom of Chinese medicine within two groups, it was showed that the clinical recovery rate of the treatment group was 40%, and the excellence rate was 27.5%, the effective rate was 25%, the total effective rate was 92.5%. While in the control group, the clinical recovery rate of the treatment group was 7.5%, and the excellence rate was 17.5%, the effective rate was 35%, the total effective rate was 60%. The total improvement rate of the symptom in Chinese medicine in both two groups were all above at 50%. To the secondary of curative effect index which including BS activity index number、BS function index、overall backache score、backache at night score and overall evaluation (VAS) score, both two groups had significant difference between before and after treatment, which all could decrease the score of the index. In the BST group, there was 7.5 percent of patients had alimentary canal complaint and 2.5 percent of patients had aleucocytosis. There was no abnormal change of liver enzyme. While in the control group, there was 12.5 percent of patients had alimentary canal complaint and 15 percent of patients had aleucocytosis. There was 5% of patients had abnormal change of liver enzyme. The adverse reaction rate of BST group was far lower than which of control group. And the adverse reaction would disappear after stopping medicine.
Conelusion
There was significant difference between two groups (P<0.05). The BST group was better than the APD group on the total curative effect of the symptom in Chinese medicine for improving the waist-sacro-back ache、backache、arthrocele、lumbar vertebrae limitation of activity、early morning stiffness、joint cold、pricking pai、Dry mouth and limbs weary (P<0.05). To the secondary of curative effect index which including BS activity index number、BS function index、overall backache score、backache at night score and overall evaluation (VAS) score, both two groups had significant difference between before and after treatment, which all could decrease the score of the index. But the BST group was better than the APD group. The analysis of safety had presented that it had not abnormal change in blood routine test、urine and stool routine test、liver and renal function test and electrocardiogram test. The BST showed that it was safe in the clinical application.
引文
[1]张恩霖.雷公藤配合中药治疗强直性脊柱炎68例[J].福建中医药,1996,27(2)：12-13.
[2]隋孝忠,于文青.补肾祛寒活络汤治疗早期强直性脊柱炎50例[J].新中医,1995,27(11)：36-37.
[3]陈忠跃,周恩庆.强直通痹汤治疗强直性脊柱炎30例[J].陕西中医,2005,26(4)：327-328.
[4]许超,童培建,肖鲁伟,等.右归饮治疗强直性脊柱炎临床疗效观察[J].中医正骨,2005,17(2)：6-7.
[5]李引刚.阳和汤治疗早期强直性脊柱炎31例[J].陕西中医,2005,26(8)：799-800.
[6]夏俊杰.朱晓鸣治疗强直性脊柱炎经验[J].湖北中医杂志,1997,19(6)：10-11.
[7]付新利.强直性脊柱炎症治浅谈[J].山东中医杂志,1992,11(5)：2-3.
[8]朱建华.强直性脊柱炎的中医证治[J].江苏中医,1992,(11)：21-23.
[9]陆肇中.强直性脊柱炎的辨证论治体会[J].天津中医,1996,13(3)：19.
[10]潘中恒,钱万永,张玄武,等.中药配合手法治疗强直性脊柱炎76例[J].中医正骨,2001,13(3)：25-26.
[11]申艳萍.益肾壮督法治强直性脊柱炎112例[J].陕西中医,2002,23(9)：803-804.
[12]张延昌.祛寒逐风合剂治疗强直性脊柱炎25例疗效分析[J].湖北中医药导报,2002,8(8)：494-495.
[13]肖泓,吴咏昕.浅谈导师治疗强直性脊柱炎的经验[J].云南中药杂志,2002,23(5)：8-9.
[14]孙青,张扣启,李海英,等.房定亚教授治疗痹证思路及用药特色[J].中医药学刊,2002,20(1)：23-25.
[15]李现林.舒督通痹汤治疗强直性脊柱炎[J].河南中药,1997,17(2)：109-110.
[16]杨勇.伸筋通痹丸治疗强直性脊柱炎134例[J].四川中医,2005,23(7)：77.
[17]肖立成.化痰补肾法治疗强直性脊柱炎24例[J].中医药学报,2002：30(2)：23-24.
[18]高根德,程春葵.扶正化痰法为主治疗强直性脊柱炎[J].上海中医药学报,1991,9：15-16.
[19]齐岩,王为兰.益痹通督方治疗强直性脊柱炎的临床与实验研究[J].北京中医,1995,6：52.
[20]邱玉珍.肾痹汤治疗强直性脊柱炎30例[J].陕西中医,1991：12(12)：62.
[21]姜萍.强直性脊柱炎的中医证治探析[J].浙江中医杂志,1995,30(2)：536-537.
[22]苗后清,闫平,刘书珍,等.化痰遂瘀解毒汤治疗强直性脊柱炎的临床研究[J].河北中医,22(8)：565.
[23]郭琳琳.强脊舒督汤治疗强直性脊柱炎38例[J].中医正骨,2005,17(8)：59.
[24]焦树德,刘志明,朱良春,等.痹证论治[J].中医杂志,1989,30(4)：4-10.
[25]王碧辉,钮淮元,符思等.身通遂瘀汤加减治疗强直性脊柱炎[J].中医杂志,1992,33(12)：35.
[26]宋绍亮.热痹证治新说[M].北京：中医古籍出版社,2005：3-192.
[27]李玮玮,栾炯.辨证治疗强直性脊柱炎36例[J].江苏中医,1994,15(8)：10.
[28]袁福林.辨证治疗强直性脊柱炎20例报告[J].中医正骨,2001,13(3)：34.
[29]张长富.辨证治疗强直性脊柱炎50例[J].陕西中医,1995,12(2)：54.
[30]陈永斌.辨证论治强直性脊椎炎21例疗效观察[J].广西医科大学学报,1997,14(1)：106
[31]焦树德.大偻(强直性脊柱炎)病因病机及辨证论治探讨(下)[J].江苏中医药,2003,24(2)：1.
[32]郭艳章.郭维淮治疗强直性脊柱炎经验[J].中国中医骨伤科杂志,1995,(5)：60.
[33]栾炯.强直性脊柱炎72例辨证论治[J].浙江中医杂志,1994,(2)：65.
[34]陆肇中.强直性脊柱炎的辨证论治体会[J].天津中医,1996,13(3)：19.
[35]马晓,阎小萍.强直性脊柱炎的辨证施治[J].中国临床医生,2002,30(5)：54.
[36]朱建华,朱婉华.强直性脊柱炎的中医证治[J].江苏中医,1992,(11)：21.
[37]陈志军,崔新生,龚环英.中医辨证分型治疗强直性脊柱炎疗效观察[J].中医临床康复,2002,6(24)：3745.
[38]程春葵,何振宝.通痹灵治疗强直性脊柱炎213例报告[J].中医正骨,1991,(3)：21.
[39]关彤.辨证分型治疗强直性脊柱炎3例疗效观察[J].湖北中医志,2001,17(3)：14-15.
[40]陈林固,郭郡浩.雷公藤合独活寄生汤治疗强直性脊柱炎临床观察[J].南京中医药大学学报,1998,14(5)：247.
[41]周运炳,陈德新,王川.蚂蚁风湿灵治疗强直性脊柱炎75例疗效观察[J].四川中医,1949,(2)：4.
[42]么远.中医辨证治疗儿童强直性脊柱炎34例[J].北京中医,1997,(1)：26.
[43]王明喜,高飞,刘景.祛邪通痹、益肾养血法治疗强直性脊柱炎的临床和实验 研究[J]。中医正骨,2003,15(5)：11.
[44]邱志济,朱建平.朱良春治疗强直性脊柱炎用药特色选析[J].辽宁中医杂志,2001,28(2)：656.
[45]李嘉庆,宋绍良.张鸣鹤经验二题[J].山东中医学院学报,1994,(3)：168-169.
[46]单书健,陈子华.古今名医临证金鉴·痹证卷(上)[M].北京：北京中医药出版社,1999：219-225.
[47]许峰,戴小明,章光华.强直性脊柱炎从肾论治的证治探讨[J].新中医,2003,25(5)：3.
[48]王凤仪.马在山老中医治疗强直性脊柱炎的经验[J].北京’中医杂志,1993,(2)：43
[49]沈峻.强直性脊柱炎的痹痿证证候传变规律探讨[J].贵阳中医学院学报,2003,25(3)：2.
[50]姜萍.尹玉茹诊治强直性脊柱炎经验[J].江苏中医,1997,18(4)：6.
[51]尤全喜.强直性脊柱炎治疗经验[N].中国中医药报,2003-08-15(3).
[52]赵诗哲.黄仰模辨治强直性脊柱炎经验[J].2003,(3)：99.
[53]许冬云,方路.舒尚义治疗强直性脊柱炎经验初探[J].云南中医中药杂志,1999,02(2)：7.
[54]候丽萍.中医治疗强直性脊柱炎412例临床观察[J].山西中医,1992,8(2)：14.
[55]张建英,针灸名医—崇桂琴[J].山东中医杂志,2003,22(11)：699.
[56]林昌松,陈纪藩,黄仰模,等.强直性脊柱炎患者中医证型分布的调查研究[J].陕西中医,2005,26(6)：548.
[57]赵永刚,陈义华,孙维梅,等.强直性脊柱炎中医辨证施治临床研究[J].中国航天医药杂志,2001,3(5)：3.
[58]张朝霞.强直性脊柱炎中医辨证小识[J].河南中医,2005,25(7)：36.
[59]林昌松.中医辨病辨证治疗强直性脊柱炎[J].新中医,2004,36(5)：5.
[60]姜泉.中医分期治疗强直性脊柱炎的临床研究[J].中医正骨,2001,13(12)：31.
[61]朱辉.莫成荣治疗强直性脊柱炎的经验[J].辽宁中医杂志,2004,31(3)184.
[62]杨富民,鲁浩,苗嵩.中药治疗强直性脊柱炎[J].辽宁中医药学院学报,2003,19(4)：25.
[63]施杞.中国中医骨伤科百家方技精华.北京：中国中医药出版社,1991：413-414.
[64]王凤仪.马在山老中医治疗强直性脊柱炎的经验.北京中医,1993,2：43-44
[65]姜萍.强直性脊柱炎的中医证治探析.浙江中医杂志,1995,30(2)：536-537.
[66]潘中恒,钱万永,张玄武,等.中药配合手法治疗强直性脊柱炎76例.中医
正骨,2001,13(3)：25-26.
[67]邓洁,冯兴华.清热利湿通络法治疗活动期强直性脊柱炎机理初探.中国中医基础医学杂志,2001,6(11)：60.
[68]姜泉.中医分期治疗强直性脊柱炎的临床研究.中医正骨,2001,13(12)：31-32.
[69]宋绍亮.热痹证治新说,北京：中医古籍出版社,2005,第一版：3-192.
[70]闫小萍.焦树德治疗强直性脊柱炎的经验.中医杂志,1994,35(7)：407-408.
[71]隋孝忠,于文青.补肾祛寒活络汤治疗早期强直性脊柱炎50例.新中医,1995,27(11)：36-37.
[72]刘红丽.骨痹汤治疗强直性脊柱炎47例.陕西中医,1998,19(11)：494-495.
[73]金笛儿,闫小萍.壮督补肾法治疗强直性脊柱炎30例临床观察.北京中医药大学学报,2002,23(4)：62-63.
[74]李现林.舒督通痹汤治疗强直性脊柱炎.河南中药,1997,17(2)：109-110
[75]戴朝寿,贺秀莲.乌头桂枝汤治疗强直性脊柱炎32例.国医论坛,1996,11(2)：16
[76]杨爱国,尹玉茹.肾痹汤治疗强直性脊柱炎30例.南京中医药大学学报,1999,13(3)：171-172.
[77]苗后清,闫平,刘书珍,等.化痰逐瘀解毒汤治疗强直性脊柱炎的临床研究.河北中医,2003,22(8)：565.
[78]周时高,陈湘君,苏励.中药内外合治强直性脊柱炎20例.南京中医药大学学报,1999,15(3)：181
[79]郭中琦,李俊兰.抗风湿散治疗强直性脊柱炎疗效观察.河北中医,2004,23(4)：267-268.
[80]曹忠贞.强脊合剂治疗强直性脊柱炎的1临床研究.广西中医药,2002,25(4)：13-14
[81]申艳萍.益肾壮督法治强直性脊柱炎112例.陕西中医,2002,23(9)：803-804
[82]张延昌.祛寒逐风合剂治疗强直性脊柱炎25例疗效分析.湖北中医药导报,2002,8(8)：494-495.
[83]肖立成.化痰补肾法治疗强直性脊柱炎24例.中医药学报,2002,30(2)：23-24.
[84]李引刚.阳和汤治疗早期强直性脊柱炎31例.陕西中医,2005,26(8)：799-800.
[85]许超,童培建,肖鲁伟,等.右归饮治疗强直性脊柱炎临床疗效观察.中医正骨,2005,17(2)：6-7.
[86]杨勇.伸筋通痹丸治疗强直性脊柱炎134例.四川中医,2005,23(7)：77.
[87]闰霞,吴云华.加味归芪六君汤治疗中晚期强直性脊柱炎32例.湖南中医杂志.2005,21(3)：56.
[88]郭琳琳.强脊舒督汤治疗强直性脊柱炎38例.中医正骨,2005,17(8)：59.
[89]陈忠跃,周恩庆.强直通痹汤治疗强直性脊柱炎30例.陕西中医,2005；26(4)：327-328.
[90]张俊莉,赵峰,陈爱琳,等.独活寄生汤加减治疗强直性脊柱炎58例.陕西中医,2005,26(6)：498-499.
[91]吴言聚.八正镇痛散加手法治疗强直性脊柱炎.中国中医骨伤科杂志,1999,7(5)：49.
[92]朱少可,祁秀荣,朱希烈.火针为主内服五香丸治疗强直性脊柱炎120例疗效观察.针灸临床杂志,1997,13(2)：26.
[93]穆晓红,高峰,和艳红,等.中药熏洗加手法治疗强直性脊柱炎.中医正骨,1998,1(9)：35.
[94]李新忠,杨雪,曹在杰,等.脊柱牵引在强直性脊柱炎康复治疗中的作用.中医正骨,1998,10(6)：13-14.
[95]曲宝萍.刮痧拔罐治疗强直性脊柱炎27例.新中医,2001,33(10)：49.
[96]罗健,孔令深,黄柳和,等.挑筋疗法治疗强直性脊柱炎临床观察.江苏中医,2001,22(11)：11-13.
[97]阎小萍.强直性脊柱炎[M].北京：中国医药科技出版社,2004：23-34.
[98]Brown MA, Pile KD, Kennedy LG, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis and Rheumatism, 1998,41 (4):588-595.
[99]Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis:evidence of non-MHC genetic-susceptibility loci. The American Journal of Human Genetics,2001,68(4):918-926.
[100]Zhang G, Luo J, Bruckel J, et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis and heumatism,2004,50(7):2246-2254.
[101]Brown MA, Crane AM, Wordsworth BP. Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis. Current opinion in rheumatology,2002,14(4):354-360.
[102]李维,吴强,余梅贵.HLA-B27亚型及其与强直性脊柱炎关系的研究进展[J].免疫学杂志,2002,18(3)：191.
[103]Hammer RE, Maika SD, Richardson JA, Tang JP, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m:an animal model of HLA-B27-associated human disorders. Cell,1990, 63(5):1099-1112.
[104]赵桐茂.HLA分型原理和应用[J].上海科技出版社,1984,208-236.
[105]赵桐茂.人类学性遗传学[M].科学出版社,1987：173,261,327.
[106]Brown MA, Pile KD, Kenn Edy LG, et al. HLA class Ⅰ association okylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dise. 1996,55:2.
[107]王英.中西譬结合治癖夙潺四病[M].北京.中医古籍出版社,1998,10：147-172.
[108]袁浩.中医骨病学[M].上海科技出版社,1999,8：49-56.
[109]Ebringer R, CawdeU DR, Cowling P, et al. Sequential studies in spondyhtis:association of Klebsiela pneumoniae with active disease. Ann Rheum Dis,1978,37:146-151.
[110]Dominguez-Lopoz ML,Cancino-Diaz ME, Jimenez-Zamudio L, et al. Cellular immune response to Klebsiella pneumoniae. antigens in patients with HLA-B27+ ankylosing spondygtis. J Rheumatol,2000,27:1453-1460.
[111]Stone M A. Payne U, et al. Comparative immune response to candidate arthritogenic bacteria do not confirm a dominant role for klebsiella pneumonia in the pathogenesis of familial ankylosing spondylitis. Rheumatol,2004,43:148.
[112]Braun J. Therapy for ankylosing spondylitis new therapeutic modalities[J]. Best Pract Res Clin Rheumatol.2002,16(4):631.
[113]Brown MA, Kennedy LG, MacGregor A J, et al Susceptibility to ankylosing spondylitis in twins:the role of genes, HLA, and the environment.Arthritis Rheum 1997,40:18-23.
[114]蒋明,DAVID,林孝义,等.中华风湿病学[M].北京：华夏社,2004：1010-1025.
[115]Espinoza LR, Aguilar JL, Espinoza CG, et al:Fibroblast function in psoriatic arthritis. I Alteration of cell kinetics and growth factor responses. J Rheumatol,1994,21:1502.
[116]黄传英.强直性脊柱炎免疫指标检测及临床价值[J].临床输血与检验,2006,8(3)187-189.
[117]Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and 1FN-gamma) in ankylosing spondylitis:a close correlation between serum IL-6 and disease activity and severity. British Journal of Rheumatology,1994,33:927-931.
[118]Isomaki P, Luukkainen R, Toivanen P, et al. The presence of interleukin-13 in rheumatoid synovium and anti-inflammatory efects on synovial fluid macrophages from patients with rheumatoid arthritis[J]. Arthritis Rheum,1996,39:169-1702.
[119]蔡安季.强直性脊柱炎发病机制的研究进展[J].放射免疫学杂志,2007,20(1)：54-57.
[120]Gratacos J, Collado A, Filella X, et al. Serum cytokines (Ⅱ,-1, IL-6, Ⅰ1-1 beta and IFN-gamma) in ankylosing spondylitis:a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol,1994 Oct,33(10):927-31.
[121]Claudepierre P, Rymer JC&Chevalier X. IL-10 plasma levels correlate with disease activity in spondyloarthropathy. The Journal of Rheumatology,1997,24:1659-1661.
[122]Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine,2002,69:123-32. M. Mansour et al. Ankylosing spondylitis. 2007 Elsevier Inc. All rights reserved. Semin Arthritis Rheum,36:210-223.
[123]Francois RJ, Gardner DL, Degrave EJ&Bywaters EG. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis and Rheumatism 2000,43:2011-2024.
[124]Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis and Rheumatism,1995,38:499-505. Bollow M, Fischer T, Reisshauer H et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T-cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancementdetected by magnetic resonance imaging. Annals of the Rheumatic Diseases,2000,59:135-140.
[125]蒋明,朱立平,林孝义.风湿病学[M].北京：科学出版社,1998：962.
[126]Loren Laine. Gastrointestinalof NSAIDs and Coxibs. Journal of Pain and Symptom Management,2003,25:S32-S40. Loren Lame. The Gastrointestinal Effects of Nonselective NSAIDs and COX-2 Selective Inhibitors. SeminArthritis Rheum 32(supply 1):25-32. R.M. Langford, V Mehta. Selective cyclooxygenase inhibition:its role in pain and anaesthesia. Biomedicine&Pharmacotherapy 60(2006):323-328.
[127]Loren Laine. Gastrointestinalof NSAIDs and Coxibs. Journal of Pain and Symptom Management,2003,25:S32-S40. Loren Lame. The Gastrointestinal Effects of Nonselective NSAIDs and COX-2 Selective Inhibitors. SeminArthritis Rheum 32(supply 1):25-32.
[128]R. M. Langford, V Mehta. Selective cyclooxygenase inhibition:its role in pain and anaesthesia. Biomedicine&Pharmacotherapy 60(2006):323-328.
[129]The Australian COX-2-Specific Inhibitor (CSD Prescribing Group. Considerations for the safe prescribing and use of the COX-2-specific inhibitors. Med J Aust 2002,176:328-331. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl Med 2004,351:1709-11.
[130]戴冽,汤美安,伊培达.柳氮磺胺毗咤在风湿病中的临床应用[J].国外医学内科学分册,2000,27(1)：28.
[131]曾小峰.中华医学会第六次全国风湿病学术会议暨第九届APLAR大会纪要[J].中华内科杂志,2000,39(11)：771.
[132]周翠英,孙素平,傅新利.风湿病中西医诊疗学[M].中国中医药出版社,1998：173.
[133]杨剑辉,梁俊林,土艳侠.环磷酞胺冲击治疗强直性脊柱炎临床观察[J].中国脊柱脊髓杂志,1995,5(2)：80.
[134]陈学军.甲氨蝶陡与柳氮磺胺毗陡联用治疗强直性脊柱炎[J].齐齐啥尔医学院学报,2004,25(2)：143-144.
[135]赵建宏.柳氮磺毗陡甲氨喋吟联合治疗强直性脊柱炎54例疗效观察[J].济宁医学院学报,2003,26(1)：38-39.
[136]张晓,戴冽,陈少峰.CT引导下骶髂关节注射治疗强直性脊柱炎[J].中华风湿病学杂志,2000,4(2)：94.
[137]MAKSYMOWYCH WP, POOLE AR, HIEBERT L, et al. Etanercept exerts beneficial efects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis[J]. J Rheumatol, 2005,32(10):1911-1917.
[138]BRAUN J, BARALIAKOS X, LISTING J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept [J]. Arthritis Rheum,2005,52(8):2447-2451.
[139]BURGOS-VARGAS R, ROJAS-SERRANO J. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis [J]. J Rheumatol, 2005,32 (9):1637-1640.
[140]Filip De Keyser, Filip Van den Bosch, Herman Mielants. Anti-TNF-alpha therapy in ankylosing spondylitis. Cytokine,2006,33:294-298.
[141]黄烽.TNF-a抑制剂治疗强直性脊柱炎研究进展[J].中国新药杂志,2006,15(11)：853-857.
[142]Van der Heijde D, Kivitz A, Schiff' MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis:results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum,2006 Jul,54(7):2136-46.
[143]Lambert RCS Salonen D, Rahman P, et al. Adalimumab si ficantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis:A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum,2007 Dec,56(12):4005-14.
[144]Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and freebisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW in vitro. Pharm Res,1995,12:916-22.
[145]Maksymowych WP, Lambert R, Jhangri GS et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol,2001,28:144-55.
[146]Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mgvs 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum, 2002,46:766-73.
[147]Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med,1993,177:1675-80.
[148]Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL-12 production by thalidomide. J Immunol, 1997,159:5157-61.
[149]LIPSKY PE, VAN DER HEIJmE DM, ST CLAIR EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trail in rheumatoid arthritis with concomitant therapy study group[J].N Eng J Med 2000,343(22):1594-1602.
[150]Van der Heijde D, Di jkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis:results of a 24-week randomized, placebo-controlled trial
(ASSERT). Presented at:Annual European Congress of Rheumatology; Berlin Germany; June 9-12,2004:SAT0053.
[151]Braun J, Baraliakos X, Golder W, Listing J, Brandt J, Bollow M, et al. Improvement in spinal inflammation in ankylosing spodylitis (AS) by infliximab therapy as assessed by a magnetic resonance imaging (MRI) using a novel evaluated spinal scoring system-results of a doubleblind placebo-controlled trial. Arthritis Rheum,2002,46(Suppl.):S426,1115.
[152]Gorman JD, Sack KE, Davis Jr. JC Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med, 2002,346 (18):1349-56.
[153]Calin A, Di jkmans BAC, Emery P, Hakala M, Kalden J, Lerisalo-Repo M, et al. A multicentre, placebo-controlled trial of Enbrel in ankylosing spondylitis. Ann Rheum Dis,2003,62(Suppl.1):OP0097.
[154]Davis JC, Van der Heijde D, Braun J. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis:a randomized controlled trial. Arthritis Rheum,2003,48(11):3230-6.
[155]Davis JC, van der Heijde DM, Braun J, Dougados M, Cush JJ, Clegg DO, et al. One-year efficacy of etanercept in ankylosing spondylitis. Presented at:Annual European Congress of Rheumatology; Berlin Germany; June 9-12,2004:SAT0044.
[156]Brandt J, Khariouzov A, Listing J, Haibel H, Rudwaleit M, Sorensen H, et al. One year follow up results of a controlled trial of a German double-blind placebo controlled trial of etanercept in active ankylosing spondylitis. Presented at:Annual European Congress of Rheumatology; Berlin Germany, June 9-12,2004:SAT0027.
[157]Braun J, Pham T, Sieper J, Davis J, van ASAS consensus statement for the use spondylitis. Ann Rheum Dis, der Linden S, Dougados M, et al. International of anti-TNF agents in patients with ankylosing.2003,62(Suppl.1):SP0172.
[158]Polley HF. The diagnosis and treatment of rheumatoid spondylitis Medclin North[J]. Am,1995,39:509.
[159]曾庆馀,肖征宇.强直性脊柱炎的临床和流行病学研究全国协作组研讨会纪要[J].中华内科杂志,1998,37(1)：52.
[160]钟建廷,叶夏云.强直性脊柱炎HLA-B27阳性和阴性患者临床分析[J].中国实用内科杂志,2002,10：606.
[161]施桂英.强直性脊柱炎35例临床分析[J].中华内科杂志,1983,6：332.
[162]冯骏.强直性脊柱炎骶髂关节病变的CT评估和临床实验室检查分析[J].实用医技杂志,2002,9(6)：409-410.
[163]刘海燕,肖丽,郭冬梅,等.强直性脊柱炎的临床、实验室与放射学关系的探讨[J].大连医科大学学报,2001,23(2)：102-103.
[164]曹铁梅,姬艳波,张希才,等.骶髂关节放射学检查在强直性脊柱炎诊断中的评价[J].中华风湿病学杂志,2002,6(3)：207-209.
[165]Wittram C, Whitehouse GH, Williams JW, et al. A comarison of MR and CT in suspected sacroilitis. J Comput Assist Tomogr,1996,23:2107-2125.
[166]Bellamy N, Park W, Rooney PH. What do we know about the sacroiliac joint?Sem in Arthritis Rheum,1983,12:282.
[167]Pepmueller PH, Moore TL. Juvenile spondyloarthropathies. Curr Opin Rheumatol,2000,12(4):269-273.
[168]冯骏.强直性脊柱炎骶髂关节病变的CT评估和临床实验室检查分析[J].实用医技杂志,2002,9(6)：409-410.
[169]曾庆馀,陈肃标.CT在AS的早期诊断和随访中的应用[J].中华风湿病学杂志,1998,12(2)：189-191.
[170]Pepmueller PH, Moore TL. Juvenile spondyloarthropatllies. Curr Opin Rheumatol,2000,12(4):269-273.
[171]曾庆馀.强直性脊柱炎早期诊断研究进展[J].中国实用内科杂志,2001,21(12)：707-709.
[172]Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. Clin Rheumatol, 2000,19(1):51-57.
[173]王伟,孙浩杰,杨宾,等.SPECT断层骨显像对早期股骨头缺血坏死的诊断价值[J].骨与关节损伤杂志,1999,14(3)：177-178.
[174]张成君,罗修文,林琛,等. 骨关节闪烁显像在强直性脊柱炎早期诊断中的价值[J].诊断学理论与实践,2004,3(4)：237-239.
[175]Pleh WC, Ho WY, Luk KD et al. Applicat ion of bone scintigraphy in ankylosing spondylitis [J]. Clin Imaging,1997,21:54-62.
[176]周华琴,潘解萍.强直性脊柱炎98例误诊分析[J].南京医科大学学报,2003,23(3)：282.
[177]蒋明.风湿病学[M].北京：科学出版社,1995：215-218.
[2]隋孝忠,于文青.补肾祛寒活络汤治疗早期强直性脊柱炎50例[J].新中医,1995,27(11)：36-37.
[3]陈忠跃,周恩庆.强直通痹汤治疗强直性脊柱炎30例[J].陕西中医,2005,26(4)：327-328.
[4]许超,童培建,肖鲁伟,等.右归饮治疗强直性脊柱炎临床疗效观察[J].中医正骨,2005,17(2)：6-7.
[5]李引刚.阳和汤治疗早期强直性脊柱炎31例[J].陕西中医,2005,26(8)：799-800.
[6]夏俊杰.朱晓鸣治疗强直性脊柱炎经验[J].湖北中医杂志,1997,19(6)：10-11.
[7]付新利.强直性脊柱炎症治浅谈[J].山东中医杂志,1992,11(5)：2-3.
[8]朱建华.强直性脊柱炎的中医证治[J].江苏中医,1992,(11)：21-23.
[9]陆肇中.强直性脊柱炎的辨证论治体会[J].天津中医,1996,13(3)：19.
[10]潘中恒,钱万永,张玄武,等.中药配合手法治疗强直性脊柱炎76例[J].中医正骨,2001,13(3)：25-26.
[11]申艳萍.益肾壮督法治强直性脊柱炎112例[J].陕西中医,2002,23(9)：803-804.
[12]张延昌.祛寒逐风合剂治疗强直性脊柱炎25例疗效分析[J].湖北中医药导报,2002,8(8)：494-495.
[13]肖泓,吴咏昕.浅谈导师治疗强直性脊柱炎的经验[J].云南中药杂志,2002,23(5)：8-9.
[14]孙青,张扣启,李海英,等.房定亚教授治疗痹证思路及用药特色[J].中医药学刊,2002,20(1)：23-25.
[15]李现林.舒督通痹汤治疗强直性脊柱炎[J].河南中药,1997,17(2)：109-110.
[16]杨勇.伸筋通痹丸治疗强直性脊柱炎134例[J].四川中医,2005,23(7)：77.
[17]肖立成.化痰补肾法治疗强直性脊柱炎24例[J].中医药学报,2002：30(2)：23-24.
[18]高根德,程春葵.扶正化痰法为主治疗强直性脊柱炎[J].上海中医药学报,1991,9：15-16.
[19]齐岩,王为兰.益痹通督方治疗强直性脊柱炎的临床与实验研究[J].北京中医,1995,6：52.
[20]邱玉珍.肾痹汤治疗强直性脊柱炎30例[J].陕西中医,1991：12(12)：62.
[21]姜萍.强直性脊柱炎的中医证治探析[J].浙江中医杂志,1995,30(2)：536-537.
[22]苗后清,闫平,刘书珍,等.化痰遂瘀解毒汤治疗强直性脊柱炎的临床研究[J].河北中医,22(8)：565.
[23]郭琳琳.强脊舒督汤治疗强直性脊柱炎38例[J].中医正骨,2005,17(8)：59.
[24]焦树德,刘志明,朱良春,等.痹证论治[J].中医杂志,1989,30(4)：4-10.
[25]王碧辉,钮淮元,符思等.身通遂瘀汤加减治疗强直性脊柱炎[J].中医杂志,1992,33(12)：35.
[26]宋绍亮.热痹证治新说[M].北京：中医古籍出版社,2005：3-192.
[27]李玮玮,栾炯.辨证治疗强直性脊柱炎36例[J].江苏中医,1994,15(8)：10.
[28]袁福林.辨证治疗强直性脊柱炎20例报告[J].中医正骨,2001,13(3)：34.
[29]张长富.辨证治疗强直性脊柱炎50例[J].陕西中医,1995,12(2)：54.
[30]陈永斌.辨证论治强直性脊椎炎21例疗效观察[J].广西医科大学学报,1997,14(1)：106
[31]焦树德.大偻(强直性脊柱炎)病因病机及辨证论治探讨(下)[J].江苏中医药,2003,24(2)：1.
[32]郭艳章.郭维淮治疗强直性脊柱炎经验[J].中国中医骨伤科杂志,1995,(5)：60.
[33]栾炯.强直性脊柱炎72例辨证论治[J].浙江中医杂志,1994,(2)：65.
[34]陆肇中.强直性脊柱炎的辨证论治体会[J].天津中医,1996,13(3)：19.
[35]马晓,阎小萍.强直性脊柱炎的辨证施治[J].中国临床医生,2002,30(5)：54.
[36]朱建华,朱婉华.强直性脊柱炎的中医证治[J].江苏中医,1992,(11)：21.
[37]陈志军,崔新生,龚环英.中医辨证分型治疗强直性脊柱炎疗效观察[J].中医临床康复,2002,6(24)：3745.
[38]程春葵,何振宝.通痹灵治疗强直性脊柱炎213例报告[J].中医正骨,1991,(3)：21.
[39]关彤.辨证分型治疗强直性脊柱炎3例疗效观察[J].湖北中医志,2001,17(3)：14-15.
[40]陈林固,郭郡浩.雷公藤合独活寄生汤治疗强直性脊柱炎临床观察[J].南京中医药大学学报,1998,14(5)：247.
[41]周运炳,陈德新,王川.蚂蚁风湿灵治疗强直性脊柱炎75例疗效观察[J].四川中医,1949,(2)：4.
[42]么远.中医辨证治疗儿童强直性脊柱炎34例[J].北京中医,1997,(1)：26.
[43]王明喜,高飞,刘景.祛邪通痹、益肾养血法治疗强直性脊柱炎的临床和实验 研究[J]。中医正骨,2003,15(5)：11.
[44]邱志济,朱建平.朱良春治疗强直性脊柱炎用药特色选析[J].辽宁中医杂志,2001,28(2)：656.
[45]李嘉庆,宋绍良.张鸣鹤经验二题[J].山东中医学院学报,1994,(3)：168-169.
[46]单书健,陈子华.古今名医临证金鉴·痹证卷(上)[M].北京：北京中医药出版社,1999：219-225.
[47]许峰,戴小明,章光华.强直性脊柱炎从肾论治的证治探讨[J].新中医,2003,25(5)：3.
[48]王凤仪.马在山老中医治疗强直性脊柱炎的经验[J].北京’中医杂志,1993,(2)：43
[49]沈峻.强直性脊柱炎的痹痿证证候传变规律探讨[J].贵阳中医学院学报,2003,25(3)：2.
[50]姜萍.尹玉茹诊治强直性脊柱炎经验[J].江苏中医,1997,18(4)：6.
[51]尤全喜.强直性脊柱炎治疗经验[N].中国中医药报,2003-08-15(3).
[52]赵诗哲.黄仰模辨治强直性脊柱炎经验[J].2003,(3)：99.
[53]许冬云,方路.舒尚义治疗强直性脊柱炎经验初探[J].云南中医中药杂志,1999,02(2)：7.
[54]候丽萍.中医治疗强直性脊柱炎412例临床观察[J].山西中医,1992,8(2)：14.
[55]张建英,针灸名医—崇桂琴[J].山东中医杂志,2003,22(11)：699.
[56]林昌松,陈纪藩,黄仰模,等.强直性脊柱炎患者中医证型分布的调查研究[J].陕西中医,2005,26(6)：548.
[57]赵永刚,陈义华,孙维梅,等.强直性脊柱炎中医辨证施治临床研究[J].中国航天医药杂志,2001,3(5)：3.
[58]张朝霞.强直性脊柱炎中医辨证小识[J].河南中医,2005,25(7)：36.
[59]林昌松.中医辨病辨证治疗强直性脊柱炎[J].新中医,2004,36(5)：5.
[60]姜泉.中医分期治疗强直性脊柱炎的临床研究[J].中医正骨,2001,13(12)：31.
[61]朱辉.莫成荣治疗强直性脊柱炎的经验[J].辽宁中医杂志,2004,31(3)184.
[62]杨富民,鲁浩,苗嵩.中药治疗强直性脊柱炎[J].辽宁中医药学院学报,2003,19(4)：25.
[63]施杞.中国中医骨伤科百家方技精华.北京：中国中医药出版社,1991：413-414.
[64]王凤仪.马在山老中医治疗强直性脊柱炎的经验.北京中医,1993,2：43-44
[65]姜萍.强直性脊柱炎的中医证治探析.浙江中医杂志,1995,30(2)：536-537.
[66]潘中恒,钱万永,张玄武,等.中药配合手法治疗强直性脊柱炎76例.中医
正骨,2001,13(3)：25-26.
[67]邓洁,冯兴华.清热利湿通络法治疗活动期强直性脊柱炎机理初探.中国中医基础医学杂志,2001,6(11)：60.
[68]姜泉.中医分期治疗强直性脊柱炎的临床研究.中医正骨,2001,13(12)：31-32.
[69]宋绍亮.热痹证治新说,北京：中医古籍出版社,2005,第一版：3-192.
[70]闫小萍.焦树德治疗强直性脊柱炎的经验.中医杂志,1994,35(7)：407-408.
[71]隋孝忠,于文青.补肾祛寒活络汤治疗早期强直性脊柱炎50例.新中医,1995,27(11)：36-37.
[72]刘红丽.骨痹汤治疗强直性脊柱炎47例.陕西中医,1998,19(11)：494-495.
[73]金笛儿,闫小萍.壮督补肾法治疗强直性脊柱炎30例临床观察.北京中医药大学学报,2002,23(4)：62-63.
[74]李现林.舒督通痹汤治疗强直性脊柱炎.河南中药,1997,17(2)：109-110
[75]戴朝寿,贺秀莲.乌头桂枝汤治疗强直性脊柱炎32例.国医论坛,1996,11(2)：16
[76]杨爱国,尹玉茹.肾痹汤治疗强直性脊柱炎30例.南京中医药大学学报,1999,13(3)：171-172.
[77]苗后清,闫平,刘书珍,等.化痰逐瘀解毒汤治疗强直性脊柱炎的临床研究.河北中医,2003,22(8)：565.
[78]周时高,陈湘君,苏励.中药内外合治强直性脊柱炎20例.南京中医药大学学报,1999,15(3)：181
[79]郭中琦,李俊兰.抗风湿散治疗强直性脊柱炎疗效观察.河北中医,2004,23(4)：267-268.
[80]曹忠贞.强脊合剂治疗强直性脊柱炎的1临床研究.广西中医药,2002,25(4)：13-14
[81]申艳萍.益肾壮督法治强直性脊柱炎112例.陕西中医,2002,23(9)：803-804
[82]张延昌.祛寒逐风合剂治疗强直性脊柱炎25例疗效分析.湖北中医药导报,2002,8(8)：494-495.
[83]肖立成.化痰补肾法治疗强直性脊柱炎24例.中医药学报,2002,30(2)：23-24.
[84]李引刚.阳和汤治疗早期强直性脊柱炎31例.陕西中医,2005,26(8)：799-800.
[85]许超,童培建,肖鲁伟,等.右归饮治疗强直性脊柱炎临床疗效观察.中医正骨,2005,17(2)：6-7.
[86]杨勇.伸筋通痹丸治疗强直性脊柱炎134例.四川中医,2005,23(7)：77.
[87]闰霞,吴云华.加味归芪六君汤治疗中晚期强直性脊柱炎32例.湖南中医杂志.2005,21(3)：56.
[88]郭琳琳.强脊舒督汤治疗强直性脊柱炎38例.中医正骨,2005,17(8)：59.
[89]陈忠跃,周恩庆.强直通痹汤治疗强直性脊柱炎30例.陕西中医,2005；26(4)：327-328.
[90]张俊莉,赵峰,陈爱琳,等.独活寄生汤加减治疗强直性脊柱炎58例.陕西中医,2005,26(6)：498-499.
[91]吴言聚.八正镇痛散加手法治疗强直性脊柱炎.中国中医骨伤科杂志,1999,7(5)：49.
[92]朱少可,祁秀荣,朱希烈.火针为主内服五香丸治疗强直性脊柱炎120例疗效观察.针灸临床杂志,1997,13(2)：26.
[93]穆晓红,高峰,和艳红,等.中药熏洗加手法治疗强直性脊柱炎.中医正骨,1998,1(9)：35.
[94]李新忠,杨雪,曹在杰,等.脊柱牵引在强直性脊柱炎康复治疗中的作用.中医正骨,1998,10(6)：13-14.
[95]曲宝萍.刮痧拔罐治疗强直性脊柱炎27例.新中医,2001,33(10)：49.
[96]罗健,孔令深,黄柳和,等.挑筋疗法治疗强直性脊柱炎临床观察.江苏中医,2001,22(11)：11-13.
[97]阎小萍.强直性脊柱炎[M].北京：中国医药科技出版社,2004：23-34.
[98]Brown MA, Pile KD, Kennedy LG, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis and Rheumatism, 1998,41 (4):588-595.
[99]Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis:evidence of non-MHC genetic-susceptibility loci. The American Journal of Human Genetics,2001,68(4):918-926.
[100]Zhang G, Luo J, Bruckel J, et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis and heumatism,2004,50(7):2246-2254.
[101]Brown MA, Crane AM, Wordsworth BP. Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis. Current opinion in rheumatology,2002,14(4):354-360.
[102]李维,吴强,余梅贵.HLA-B27亚型及其与强直性脊柱炎关系的研究进展[J].免疫学杂志,2002,18(3)：191.
[103]Hammer RE, Maika SD, Richardson JA, Tang JP, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m:an animal model of HLA-B27-associated human disorders. Cell,1990, 63(5):1099-1112.
[104]赵桐茂.HLA分型原理和应用[J].上海科技出版社,1984,208-236.
[105]赵桐茂.人类学性遗传学[M].科学出版社,1987：173,261,327.
[106]Brown MA, Pile KD, Kenn Edy LG, et al. HLA class Ⅰ association okylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dise. 1996,55:2.
[107]王英.中西譬结合治癖夙潺四病[M].北京.中医古籍出版社,1998,10：147-172.
[108]袁浩.中医骨病学[M].上海科技出版社,1999,8：49-56.
[109]Ebringer R, CawdeU DR, Cowling P, et al. Sequential studies in spondyhtis:association of Klebsiela pneumoniae with active disease. Ann Rheum Dis,1978,37:146-151.
[110]Dominguez-Lopoz ML,Cancino-Diaz ME, Jimenez-Zamudio L, et al. Cellular immune response to Klebsiella pneumoniae. antigens in patients with HLA-B27+ ankylosing spondygtis. J Rheumatol,2000,27:1453-1460.
[111]Stone M A. Payne U, et al. Comparative immune response to candidate arthritogenic bacteria do not confirm a dominant role for klebsiella pneumonia in the pathogenesis of familial ankylosing spondylitis. Rheumatol,2004,43:148.
[112]Braun J. Therapy for ankylosing spondylitis new therapeutic modalities[J]. Best Pract Res Clin Rheumatol.2002,16(4):631.
[113]Brown MA, Kennedy LG, MacGregor A J, et al Susceptibility to ankylosing spondylitis in twins:the role of genes, HLA, and the environment.Arthritis Rheum 1997,40:18-23.
[114]蒋明,DAVID,林孝义,等.中华风湿病学[M].北京：华夏社,2004：1010-1025.
[115]Espinoza LR, Aguilar JL, Espinoza CG, et al:Fibroblast function in psoriatic arthritis. I Alteration of cell kinetics and growth factor responses. J Rheumatol,1994,21:1502.
[116]黄传英.强直性脊柱炎免疫指标检测及临床价值[J].临床输血与检验,2006,8(3)187-189.
[117]Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and 1FN-gamma) in ankylosing spondylitis:a close correlation between serum IL-6 and disease activity and severity. British Journal of Rheumatology,1994,33:927-931.
[118]Isomaki P, Luukkainen R, Toivanen P, et al. The presence of interleukin-13 in rheumatoid synovium and anti-inflammatory efects on synovial fluid macrophages from patients with rheumatoid arthritis[J]. Arthritis Rheum,1996,39:169-1702.
[119]蔡安季.强直性脊柱炎发病机制的研究进展[J].放射免疫学杂志,2007,20(1)：54-57.
[120]Gratacos J, Collado A, Filella X, et al. Serum cytokines (Ⅱ,-1, IL-6, Ⅰ1-1 beta and IFN-gamma) in ankylosing spondylitis:a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol,1994 Oct,33(10):927-31.
[121]Claudepierre P, Rymer JC&Chevalier X. IL-10 plasma levels correlate with disease activity in spondyloarthropathy. The Journal of Rheumatology,1997,24:1659-1661.
[122]Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine,2002,69:123-32. M. Mansour et al. Ankylosing spondylitis. 2007 Elsevier Inc. All rights reserved. Semin Arthritis Rheum,36:210-223.
[123]Francois RJ, Gardner DL, Degrave EJ&Bywaters EG. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis and Rheumatism 2000,43:2011-2024.
[124]Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis and Rheumatism,1995,38:499-505. Bollow M, Fischer T, Reisshauer H et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T-cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancementdetected by magnetic resonance imaging. Annals of the Rheumatic Diseases,2000,59:135-140.
[125]蒋明,朱立平,林孝义.风湿病学[M].北京：科学出版社,1998：962.
[126]Loren Laine. Gastrointestinalof NSAIDs and Coxibs. Journal of Pain and Symptom Management,2003,25:S32-S40. Loren Lame. The Gastrointestinal Effects of Nonselective NSAIDs and COX-2 Selective Inhibitors. SeminArthritis Rheum 32(supply 1):25-32. R.M. Langford, V Mehta. Selective cyclooxygenase inhibition:its role in pain and anaesthesia. Biomedicine&Pharmacotherapy 60(2006):323-328.
[127]Loren Laine. Gastrointestinalof NSAIDs and Coxibs. Journal of Pain and Symptom Management,2003,25:S32-S40. Loren Lame. The Gastrointestinal Effects of Nonselective NSAIDs and COX-2 Selective Inhibitors. SeminArthritis Rheum 32(supply 1):25-32.
[128]R. M. Langford, V Mehta. Selective cyclooxygenase inhibition:its role in pain and anaesthesia. Biomedicine&Pharmacotherapy 60(2006):323-328.
[129]The Australian COX-2-Specific Inhibitor (CSD Prescribing Group. Considerations for the safe prescribing and use of the COX-2-specific inhibitors. Med J Aust 2002,176:328-331. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl Med 2004,351:1709-11.
[130]戴冽,汤美安,伊培达.柳氮磺胺毗咤在风湿病中的临床应用[J].国外医学内科学分册,2000,27(1)：28.
[131]曾小峰.中华医学会第六次全国风湿病学术会议暨第九届APLAR大会纪要[J].中华内科杂志,2000,39(11)：771.
[132]周翠英,孙素平,傅新利.风湿病中西医诊疗学[M].中国中医药出版社,1998：173.
[133]杨剑辉,梁俊林,土艳侠.环磷酞胺冲击治疗强直性脊柱炎临床观察[J].中国脊柱脊髓杂志,1995,5(2)：80.
[134]陈学军.甲氨蝶陡与柳氮磺胺毗陡联用治疗强直性脊柱炎[J].齐齐啥尔医学院学报,2004,25(2)：143-144.
[135]赵建宏.柳氮磺毗陡甲氨喋吟联合治疗强直性脊柱炎54例疗效观察[J].济宁医学院学报,2003,26(1)：38-39.
[136]张晓,戴冽,陈少峰.CT引导下骶髂关节注射治疗强直性脊柱炎[J].中华风湿病学杂志,2000,4(2)：94.
[137]MAKSYMOWYCH WP, POOLE AR, HIEBERT L, et al. Etanercept exerts beneficial efects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis[J]. J Rheumatol, 2005,32(10):1911-1917.
[138]BRAUN J, BARALIAKOS X, LISTING J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept [J]. Arthritis Rheum,2005,52(8):2447-2451.
[139]BURGOS-VARGAS R, ROJAS-SERRANO J. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis [J]. J Rheumatol, 2005,32 (9):1637-1640.
[140]Filip De Keyser, Filip Van den Bosch, Herman Mielants. Anti-TNF-alpha therapy in ankylosing spondylitis. Cytokine,2006,33:294-298.
[141]黄烽.TNF-a抑制剂治疗强直性脊柱炎研究进展[J].中国新药杂志,2006,15(11)：853-857.
[142]Van der Heijde D, Kivitz A, Schiff' MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis:results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum,2006 Jul,54(7):2136-46.
[143]Lambert RCS Salonen D, Rahman P, et al. Adalimumab si ficantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis:A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum,2007 Dec,56(12):4005-14.
[144]Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and freebisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW in vitro. Pharm Res,1995,12:916-22.
[145]Maksymowych WP, Lambert R, Jhangri GS et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol,2001,28:144-55.
[146]Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mgvs 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum, 2002,46:766-73.
[147]Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med,1993,177:1675-80.
[148]Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL-12 production by thalidomide. J Immunol, 1997,159:5157-61.
[149]LIPSKY PE, VAN DER HEIJmE DM, ST CLAIR EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trail in rheumatoid arthritis with concomitant therapy study group[J].N Eng J Med 2000,343(22):1594-1602.
[150]Van der Heijde D, Di jkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis:results of a 24-week randomized, placebo-controlled trial
(ASSERT). Presented at:Annual European Congress of Rheumatology; Berlin Germany; June 9-12,2004:SAT0053.
[151]Braun J, Baraliakos X, Golder W, Listing J, Brandt J, Bollow M, et al. Improvement in spinal inflammation in ankylosing spodylitis (AS) by infliximab therapy as assessed by a magnetic resonance imaging (MRI) using a novel evaluated spinal scoring system-results of a doubleblind placebo-controlled trial. Arthritis Rheum,2002,46(Suppl.):S426,1115.
[152]Gorman JD, Sack KE, Davis Jr. JC Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med, 2002,346 (18):1349-56.
[153]Calin A, Di jkmans BAC, Emery P, Hakala M, Kalden J, Lerisalo-Repo M, et al. A multicentre, placebo-controlled trial of Enbrel in ankylosing spondylitis. Ann Rheum Dis,2003,62(Suppl.1):OP0097.
[154]Davis JC, Van der Heijde D, Braun J. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis:a randomized controlled trial. Arthritis Rheum,2003,48(11):3230-6.
[155]Davis JC, van der Heijde DM, Braun J, Dougados M, Cush JJ, Clegg DO, et al. One-year efficacy of etanercept in ankylosing spondylitis. Presented at:Annual European Congress of Rheumatology; Berlin Germany; June 9-12,2004:SAT0044.
[156]Brandt J, Khariouzov A, Listing J, Haibel H, Rudwaleit M, Sorensen H, et al. One year follow up results of a controlled trial of a German double-blind placebo controlled trial of etanercept in active ankylosing spondylitis. Presented at:Annual European Congress of Rheumatology; Berlin Germany, June 9-12,2004:SAT0027.
[157]Braun J, Pham T, Sieper J, Davis J, van ASAS consensus statement for the use spondylitis. Ann Rheum Dis, der Linden S, Dougados M, et al. International of anti-TNF agents in patients with ankylosing.2003,62(Suppl.1):SP0172.
[158]Polley HF. The diagnosis and treatment of rheumatoid spondylitis Medclin North[J]. Am,1995,39:509.
[159]曾庆馀,肖征宇.强直性脊柱炎的临床和流行病学研究全国协作组研讨会纪要[J].中华内科杂志,1998,37(1)：52.
[160]钟建廷,叶夏云.强直性脊柱炎HLA-B27阳性和阴性患者临床分析[J].中国实用内科杂志,2002,10：606.
[161]施桂英.强直性脊柱炎35例临床分析[J].中华内科杂志,1983,6：332.
[162]冯骏.强直性脊柱炎骶髂关节病变的CT评估和临床实验室检查分析[J].实用医技杂志,2002,9(6)：409-410.
[163]刘海燕,肖丽,郭冬梅,等.强直性脊柱炎的临床、实验室与放射学关系的探讨[J].大连医科大学学报,2001,23(2)：102-103.
[164]曹铁梅,姬艳波,张希才,等.骶髂关节放射学检查在强直性脊柱炎诊断中的评价[J].中华风湿病学杂志,2002,6(3)：207-209.
[165]Wittram C, Whitehouse GH, Williams JW, et al. A comarison of MR and CT in suspected sacroilitis. J Comput Assist Tomogr,1996,23:2107-2125.
[166]Bellamy N, Park W, Rooney PH. What do we know about the sacroiliac joint?Sem in Arthritis Rheum,1983,12:282.
[167]Pepmueller PH, Moore TL. Juvenile spondyloarthropathies. Curr Opin Rheumatol,2000,12(4):269-273.
[168]冯骏.强直性脊柱炎骶髂关节病变的CT评估和临床实验室检查分析[J].实用医技杂志,2002,9(6)：409-410.
[169]曾庆馀,陈肃标.CT在AS的早期诊断和随访中的应用[J].中华风湿病学杂志,1998,12(2)：189-191.
[170]Pepmueller PH, Moore TL. Juvenile spondyloarthropatllies. Curr Opin Rheumatol,2000,12(4):269-273.
[171]曾庆馀.强直性脊柱炎早期诊断研究进展[J].中国实用内科杂志,2001,21(12)：707-709.
[172]Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. Clin Rheumatol, 2000,19(1):51-57.
[173]王伟,孙浩杰,杨宾,等.SPECT断层骨显像对早期股骨头缺血坏死的诊断价值[J].骨与关节损伤杂志,1999,14(3)：177-178.
[174]张成君,罗修文,林琛,等. 骨关节闪烁显像在强直性脊柱炎早期诊断中的价值[J].诊断学理论与实践,2004,3(4)：237-239.
[175]Pleh WC, Ho WY, Luk KD et al. Applicat ion of bone scintigraphy in ankylosing spondylitis [J]. Clin Imaging,1997,21:54-62.
[176]周华琴,潘解萍.强直性脊柱炎98例误诊分析[J].南京医科大学学报,2003,23(3)：282.
[177]蒋明.风湿病学[M].北京：科学出版社,1995：215-218.